Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
Healthcare
$15.78 -0.39%
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
52W Low $7.91High $28.72
Volume 1.07M
Average 1.17M
Income Statement
Follow revenue through to earnings.
Revenue
$247.00M
FY 2025 · Annual
-4.3% YoYOperating Income
-$386.00M
FY 2025 · Annual
Net Income
-$353.00M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 383M | 112M | 117M | 258M | 247M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 10M |
| Gross Profit | 383M | 112M | 117M | 258M | 237M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.0% |
| Research & Development | 257M | 288M | 340M | 448M | 523M |
| Selling, General & Admin | 72M | 104M | 117M | 120M | 110M |
| Operating Expenses | 329M | 392M | 457M | 588M | 623M |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| EBITDA | 59M | (258M) | (291M) | (269M) | (335M) |
| EBITDA Margin | 15.4% | -230.4% | -248.7% | -104.3% | -135.6% |
| Operating Income | 54M | (280M) | (340M) | (330M) | (386M) |
| Operating Margin | 14.1% | -250.0% | -290.6% | -127.9% | -156.3% |
| Interest Income | 1M | 16M | 41M | 52M | 41M |
| Interest Expense | 0 | 2M | 2M | 4M | 8M |
| Other Income / Expenses | 1M | 14M | 39M | 47M | 33M |
| Income Before Tax | 55M | (266M) | (301M) | (283M) | (353M) |
| Pre-Tax Margin | 14.4% | -237.5% | -257.3% | -109.7% | -142.9% |
| Income Tax Expense | 2M | 1M | 6M | 1M | 0 |
| Net Income | 53M | (267M) | (307M) | (283M) | (353M) |
| Net Margin | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% |
| EPS (Basic) | 0.76 | (3.71) | (4.15) | (3.14) | (3.29) |
| EPS (Diluted) | 0.71 | (3.71) | (4.15) | (3.14) | (3.29) |
| 69.35M | 72M | 74M | 90.1M | 107.4M | |
| 73.97M | 72M | 74M | 90.1M | 107.4M |
RCUS Earnings Waterfall · TTM
NYSE:RCUS · Revenue to Net Income
Key Ratios
EPS$-3.93
Gross Margin92.9%
Net Margin-447.8%
P/E Ratio-6.3
P/S Ratio96.9
Analysis
$117.0M of revenue converted into -$452.0M of net income for the selected period. Gross margin is 92.9% and net margin is -447.8%, showing how much revenue survives after costs and taxes. EPS is $-3.93, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 8-K | Current report | Oct 23, 2026 | |
| 424B5 | 424B5 filing | Oct 22, 2026 | |
| 8-K | Current report | Oct 21, 2026 |
How much revenue does RCUS generate?
Arcus Biosciences, Inc. (RCUS) reported $247.00M of revenue in fiscal 2025.
Is RCUS profitable?
Arcus Biosciences, Inc. (RCUS) reported -$353.00M of net income, with a net margin of -142.9%.
Continue the stock analysis
Jump to another research area for this company.